



Financial Tear Sheet

Corporate Profile

T2 Biosystems is focused on developing innovative diagnostic products to improve patient health. With two FDA-cleared products targeting sepsis and a range of additional products in development, T2 Biosystems is an emerging leader in the field of in vitro diagnostics. The Company is utilizing its proprietary T2 Magnetic Resonance platform, or T2MR®, to develop a broad set of applications aimed at lowering mortality rates, improving patient outcomes and reducing the cost of healthcare by helping medical professionals make targeted treatment decisions earlier. T2MR enables the fast and sensitive detection of pathogens, biomarkers and other abnormalities in a variety of unpurified patient sample types, including whole blood, eliminating the time-consuming sample prep required in current methods. For more information, please visit www.t2biosystems.com.

Primary IR Contact

Investor

Contact Information

E-mail:

ir@T2Biosystems.com

Stock Performance

TTOO (Common Stock)

Exchange	NASDAQ (US Dollar)
Price	\$3.87
Change (%)	▼ 0.13 (3.25%)
Volume	1,630,332
52 Week Low	\$3.02
Market Cap	\$118,400,104
Rolling EPS	-2.05
PE Ratio	0
Shares Outstanding	30,594,342

Data as of 06/23/17 4:00 p.m. ET



Data provided by Nasdaq. Minimum 15 minutes delayed.

Recent Headlines & Events

06/19/17 - 8:00 a.m.
T2 Biosystems Chief Scientific Officer Tom Lowery to Present at BIO 2017 Convention

06/08/17 - 8:01 a.m.
T2 Biosystems to Present at the 2017 Marcum Microcap Conference

06/07/17 - 8:02 a.m.
T2 Biosystems Announces New T2Sepsis Solution™ Clinical and Economic Results Presented by Leading Experts at ASM Microbe 2017 Conference

There are currently no events scheduled.

SEC Filings

Filing Date	Form
06/08/17	4
06/08/17	4
06/08/17	4
06/08/17	4

Corporate Governance

John McDonough	Chief Executive Officer
Joanne Spadaro, Ph.D.	Chief Operations Officer
Tom Lowery, Ph.D.	Chief Scientific Officer
David P. Harding	Chief Commercial Officer
Michael A. Pfaller, MD	Chief Medical Officer
Rahul Dhanda	Senior Vice President, Corporate Development
Michael Gibbs, Esq.	Vice President and General Counsel
Alec Barclay	VP, Product Development & Program Management